nac glutathione liver protection aas Clinical use of N-acetyl cysteine during transplantation: Implications of oxidative stress and inflammation as therapeutic targets NAC & Glutathione: The Ultimate

enthusiasm dramatically outpaces science FDA Category 2 classifications for peptides like Semax reflect absence of FDA-standard evidence, not documented harmsRussian clinical experience suggests reasonable safety, but long-term effects by Western standards remain uncharacterized Established interventionsexercise, Mediterranean diet, sleep optimization, cardiovascular risk management, cognitive engagementhave far more consistent evidence than any peptide for dementia risk reduction For Research Prioritization Compounds meriting continued investigation: GLP-1 Agonists: Prevention trials in preclinical/presymptomatic populations, testing compounds with better brain penetration (dulaglutide, lixisenatide) SS-31/Elamipretide: Cognitive outcomes in mitochondrial disease populations, potential expansion to brain aging indications P21: Phase I human trials to establish safety, pharmacokinetics, and proof-of-mechanism for CNTF-pathway neurogenesis Klotho: Watch for Phase 1 results from Jocasta Neuroscience (expected 2027-2028)

"Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes"

Sep 2012;46(3):152-7

TRPM7 and TRPM2-Candidate susceptibility genes for Western Pacific ALS and PD

Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation

The cost reflects not just the amount of NAD used but the extended clinician presence, monitoring and scheduling required for these long sessions